MacroGenics (M55) Stock Forecast & Price Target

5 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

M55 Analyst Ratings

Moderate Buy

2 Buy

2 Hold

0 Sell

Based on 4 analysts giving stock ratings to

MacroGenics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

M55 Stock 12 Month Forecast

Average Price Target

€5.49

▲(72.69% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for MacroGenics in the last 3 months. The average price target is €5.49 with a high forecast of €7.80 and a low forecast of €3.47. The average price target represents a 72.69% change from the last price of €3.18.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","2":"€2","4":"€4","6":"€6","8":"€8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7.80399144,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€7.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.491697680000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€5.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.46844064,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€3.47</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2,4,6,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.24,3.591076264615385,3.9421525292307695,4.293228793846154,4.644305058461539,4.9953813230769235,5.346457587692308,5.697533852307693,6.0486101169230775,6.399686381538462,6.750762646153847,7.1018389107692315,7.452915175384615,{"y":7.80399144,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.24,3.413207513846154,3.586415027692308,3.759622541538462,3.9328300553846156,4.10603756923077,4.2792450830769235,4.452452596923077,4.625660110769231,4.798867624615385,4.972075138461539,5.145282652307693,5.318490166153847,{"y":5.491697680000001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.24,3.257572356923077,3.275144713846154,3.292717070769231,3.310289427692308,3.3278617846153846,3.3454341415384614,3.3630064984615387,3.3805788553846154,3.3981512123076922,3.415723569230769,3.4332959261538463,3.450868283076923,{"y":3.46844064,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.356,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.415,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.317,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.315,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.523,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.628,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.46,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.54,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.24,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€7.80

Average Price Target€5.49

Lowest Price Target€3.47

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Stephen Willey

Stifel Nicolaus

€3.47

Hold

9.07%

Upside

Reiterated

07/24/26

MacroGenics (MGNX) Receives a Hold from Stifel Nicolaus

Mayank Mamtani

B. Riley Securities

€7.8

Buy

145.41%

Upside

Reiterated

05/22/26

Analysts Offer Insights on Healthcare Companies: MacroGenics (NASDAQ: MGNX), Bristol-Myers Squibb (NYSE: BMY) and Pelthos Therapeutics (NYSE MKT: PTHS)

Etzer Darout

Barclays

€5.2

Buy

63.61%

Upside

Assigned

05/13/26

Barclays Reaffirms Their Buy Rating on MacroGenics (MGNX)

Robert Burns

H.C. Wainwright

―

Hold

―

Reiterated

05/07/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Agilon Health (NYSE: AGL), Lyell Immunopharma (NASDAQ: LYEL) and MacroGenics (NASDAQ: MGNX)

Tara Bancroft

TD Cowen

―

Hold

―

Assigned

03/10/26

Analysts Offer Insights on Healthcare Companies: MacroGenics (NASDAQ: MGNX) and Cartesian Therapeutics (NASDAQ: RNAC)

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

€2.6

Buy

-18.20%

Downside

Initiated

09/17/25

MacroGenics (MGNX) Initiated with a Buy at Roth MKM

Jonathan Chang

Leerink Partners

€6.94→€4.34

Buy

36.34%

Upside

Reiterated

08/18/25

MacroGenics price target lowered to $5 from $8 at LeerinkMacroGenics price target lowered to $5 from $8 at Leerink

Silvan Tuerkcan

Citizens JMP

―

Hold

―

Reiterated

08/15/25

Citizens JMP Keeps Their Hold Rating on MacroGenics (MGNX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Stephen Willey

Stifel Nicolaus

€3.47

Hold

9.07%

Upside

Reiterated

07/24/26

MacroGenics (MGNX) Receives a Hold from Stifel Nicolaus

Mayank Mamtani

B. Riley Securities

€7.8

Buy

145.41%

Upside

Reiterated

05/22/26

Analysts Offer Insights on Healthcare Companies: MacroGenics (NASDAQ: MGNX), Bristol-Myers Squibb (NYSE: BMY) and Pelthos Therapeutics (NYSE MKT: PTHS)

Etzer Darout

Barclays

€5.2

Buy

63.61%

Upside

Assigned

05/13/26

Barclays Reaffirms Their Buy Rating on MacroGenics (MGNX)

Robert Burns

H.C. Wainwright

―

Hold

―

Reiterated

05/07/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Agilon Health (NYSE: AGL), Lyell Immunopharma (NASDAQ: LYEL) and MacroGenics (NASDAQ: MGNX)

Tara Bancroft

TD Cowen

―

Hold

―

Assigned

03/10/26

Analysts Offer Insights on Healthcare Companies: MacroGenics (NASDAQ: MGNX) and Cartesian Therapeutics (NASDAQ: RNAC)

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

€2.6

Buy

-18.20%

Downside

Initiated

09/17/25

MacroGenics (MGNX) Initiated with a Buy at Roth MKM

Jonathan Chang

Leerink Partners

€6.94→€4.34

Buy

36.34%

Upside

Reiterated

08/18/25

MacroGenics price target lowered to $5 from $8 at LeerinkMacroGenics price target lowered to $5 from $8 at Leerink

Silvan Tuerkcan

Citizens JMP

―

Hold

―

Reiterated

08/15/25

Citizens JMP Keeps Their Hold Rating on MacroGenics (MGNX)

Stocks with the Highest Top Analyst Consensus in the General Sector

SKHYSK Hynix

ITGITG Inc. Class A

LIMENeutron Holdings, Inc.

EROCERock

CBRSCerebras Systems, Inc. Class A

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering MacroGenics

3 Months

Etzer DaroutBarclays

Success Rate

9/17 ratings generated profit

Average Return

+2.85%

Copying Etzer Darout's trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +2.85% per trade.

1 Year

Etzer DaroutBarclays

Success Rate

10/17 ratings generated profit

Average Return

+21.68%

Copying Etzer Darout's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of +21.68% per trade.

2 Years

Etzer DaroutBarclays

Success Rate

6/17 ratings generated profit

Average Return

-15.46%

Copying Etzer Darout's trades and holding each position for 2 Years would result in 35.29% of your transactions generating a profit, with an average return of -15.46% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

M55 Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, M55 has received 0 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. M55 average Analyst price target in the past 3 months is 5.49.

Each month's total comprises the sum of three months' worth of ratings.

M55 Financial Forecast

M55 Earnings Forecast

Next quarter’s earnings estimate for M55 is -€0.07 with a range of -€0.61 to €1.48. The previous quarter’s EPS was -€0.50. M55 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 49.94% of the time in the same period. In the last calendar year M55 has Performed in-line its overall industry.

M55 Sales Forecast

Next quarter’s sales forecast for M55 is €51.29M with a range of €12.92M to €151.09M. The previous quarter’s sales results were €18.02M. M55 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 62.37% of the time in the same period. In the last calendar year M55 has Performed in-line its overall industry.

M55 Stock Forecast FAQ

What is DE:M55’s average 12-month price target, according to analysts?

Based on analyst ratings, MacroGenics’s 12-month average price target is 5.49.

What is DE:M55’s upside potential, based on the analysts’ average price target?

MacroGenics has 72.69% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MacroGenics a Buy, Sell or Hold?

MacroGenics has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 2 hold ratings and 0 sell ratings.

What is MacroGenics’s share price target?

The average share price target for MacroGenics is 5.49. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €7.80 ,and the lowest forecast is €3.47. The average share price target represents 72.69% Increase from the current price of €3.18.

What do analysts say about MacroGenics?

MacroGenics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of MacroGenics?

To buy shares of DE:M55, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

MacroGenics (M55) Stock Forecast & Price Target

M55 Analyst Ratings

M55 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering MacroGenics

M55 Analyst Recommendation Trends

M55 Financial Forecast

M55 Earnings Forecast

M55 Sales Forecast

M55 Stock Forecast FAQ

Detailed List of Analyst Forecasts